QQ客服 官方微博 反馈留言

浏览/检索结果: 共21条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study 期刊论文 2019, 卷号: 8, 期号: 13, 页码: 5823-5830 作者:  Yang Guangjian;  Ma Di;  Xu Haiyan;  Yang Lu;  Li Junling 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 anaplastic lymphoma kinase inhibitor  crizotinib  crizotinib continuation beyond progressive disease  non-small cell lung cancer  treatment duration   Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer 期刊论文 2019 作者:  Xing Puyuan;  Han Xiaohong;  Wang Sha;  Liu Yutao;  Yang Sheng 收藏  |  浏览/下载：21/0  |  提交时间：2020/01/03 circulating tumour DNA  non-small-cell lung cancer  osimertinib  resistance   Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study 期刊论文 2019, 卷号: 31, 期号: 3, 页码: 481-+ 作者:  Xing, Puyuan;  Ma, Di;  Wang, Qiang;  Hao, Xuezhi;  Wang, Mengzhao 收藏  |  浏览/下载：15/0  |  提交时间：2020/01/03 Crizotinib  anaplastic lymphoma kinase  non-small-cell lung cancer  real-world study   Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma 期刊论文 2019, 卷号: 9, 页码: 556 作者:  Han, Xiaohong;  Tan, Qiaoyun;  Yang, Sheng;  Li, Junling;  Xu, Jianping 收藏  |  浏览/下载：19/0  |  提交时间：2020/01/03 lung adenocarcinoma  copy number alteration  prognosis  predict  adjuvant chemotherapy   Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment 期刊论文 2019, 卷号: 31, 期号: 2, 页码: 349-356 作者:  Xu, Haiyan;  Ma, Di;  Yang, Guangjian;  Li, Junling;  Hao, Xuezhi 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 ALK  crizotinib  non-small-cell lung cancer  resistance  sequential therapy   Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib 期刊论文 2019, 卷号: 14, 期号: 3, 页码: 335-342 作者:  Mu, Yuxin;  Hao, Xuezhi;  Yang, Ke;  Ma, Di;  Wang, Shouzheng 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib 期刊论文 2019, 卷号: 10, 期号: 5, 页码: 1213-1219 作者:  Ma, Di;  Zhang, Yan;  Xing, Puyuan;  Hao, Xuezhi;  Wang, Mengzhao 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 Anaplastic lymphoma kinase  crizotinib  non-small cell lung cancer  primary resistance   Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China 期刊论文 2019, 卷号: 14, 期号: 3, 页码: 325-333 作者:  Xing, Puyuan;  Wang, Shouzheng;  Wang, Qiang;  Ma, Di;  Hao, Xuezhi 收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03 二甲双胍临床应用专家共识(2018年版) 期刊论文 2019, 卷号: 16, 期号: 5, 页码: 3-15 作者:  母义明;  纪立农;  宁光;  李光伟;  单忠艳 收藏  |  浏览/下载：17/0  |  提交时间：2020/01/03 二甲双胍  临床应用  2018年版   Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations 期刊论文 2019, 卷号: 10, 期号: 6, 页码: 1461-1468 作者:  Wang, Shouzheng;  Xing, Puyuan;  Yang, Ke;  Hao, Xuezhi;  Ma, Di 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 Afatinib  lung adenocarcinoma  non-small-cell lung  ErbB receptors  molecular targeted therapy